CATSmart, Automated Blood Processing Autotransfusion System

K210089 · Fresenius Kabi AG · CAC · Feb 11, 2021 · Anesthesiology

Device Facts

• Record ID: K210089
• Device Name: CATSmart, Automated Blood Processing Autotransfusion System
• Applicant: Fresenius Kabi AG
• Product Code: CAC · Anesthesiology
• Decision Date: Feb 11, 2021
• Decision: SESE
• Submission Type: Special
• Regulation: 21 CFR 868.5830
• Device Class: Class 2
• Attributes: Therapeutic

Intended Use

The CATSmart System by Fresenius Kabi is an autotransfusion device indicated for the processing of autologous shed blood collected intraoperatively and postoperatively to obtain washed red blood cells for reinfusion. Additionally, it can be used for perioperative separation of blood into Packed Red Cells (PRC), Plasma (PLS) and Platelet Rich Plasma (PRP).

Device Story

CATSmart is an automated autotransfusion system; processes anticoagulated shed blood collected intraoperatively or postoperatively. Operates via continuous flow centrifuge; removes plasma, non-erythrocytic cellular components, activated coagulation factors, fibrinolysis products, and anticoagulants. Produces washed packed red blood cells for reinfusion; also separates blood into PRC, PLS, and PRP. Used in clinical settings; operated by trained personnel. System utilizes disposable sets and accessories to facilitate blood processing. Output allows clinicians to provide autologous blood transfusion, reducing need for allogeneic blood products and potentially improving patient outcomes by returning patient's own red cells.

Clinical Evidence

No clinical data was required or provided for this submission. Substantial equivalence is supported by bench testing, including sterility assurance, bioburden testing, bacterial endotoxin verification, and performance qualification of the sterilization process (biological indicators, temperature mapping, and residual testing).

Technological Characteristics

Continuous flow centrifuge autotransfusion system. Utilizes disposable sets and accessories. Sterilization via ethylene oxide. No changes to materials or design from predicate. System is intended for clinical use.

Indications for Use

Indicated for patients undergoing surgery or trauma requiring autologous blood processing; used for intraoperative and postoperative collection and washing of shed blood for reinfusion, or perioperative separation into PRC, PLS, and PRP.

Regulatory Classification

Identification

An autotransfusion apparatus is a device used to collect and reinfuse the blood lost by a patient due to surgery or trauma.

Predicate Devices

• CATSmart (K192368)

Submission Summary (Full Text)

{0}------------------------------------------------

Image /page/0/Picture/0 description: The image shows the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is the FDA logo, with the letters "FDA" in a blue square. To the right of the blue square is the text "U.S. FOOD & DRUG ADMINISTRATION" in blue.

February 11, 2021

Fresenius Kabi AG % Cheryl Roscher Vice President, Regulatory and Clinical Affairs Fresenius Kabi Three Corporate Drive Lake Zurich, Illinois 60047

Re: K210089

Trade/Device Name: CATSmart Regulation Number: 21 CFR 868.5830 Regulation Name: Autotransfusion Apparatus Regulatory Class: Class II Product Code: CAC Dated: January 12, 2021 Received: January 13, 2021

Dear Cheryl Roscher:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal

{1}------------------------------------------------

statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email ([e-mail]) or phone [phone] or 301-796-7100).

Sincerely,

Fernando Aguel Assistant Director DHT2B: Division of Circulatory Support, Structural and Vascular Devices OHT2: Office of Cardiovascular Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health

Enclosure

{2}------------------------------------------------

# Indications for Use

510(k) Number (if known)

K210089

Device Name CATSmart

Indications for Use (Describe)

The CATSmart System by Fresenius Kabi is an autotransfusion device indicated for the processing of autologous shed blood collected intraoperatively and postoperatively to obtain washed red blood cells for reinfusion. Additionally, it can be used for perioperative separation of blood into Packed Red Cells (PRC), Plasma (PLS) and Platelet Rich Plasma (PRP).

| Type of Use (Select one or both, as applicable) | | |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|------------------------------------------------------------------------------------|
| <table border="0"><tr><td><span style="font-size:120%;">☑</span> Prescription Use (Part 21 CFR 801 Subpart D) </td></tr><tr><td><span style="font-size:120%;">☐</span> Over-The-Counter Use (21 CFR 801 Subpart C) </td></tr></table> | <span style="font-size:120%;">☑</span> Prescription Use (Part 21 CFR 801 Subpart D) | <span style="font-size:120%;">☐</span> Over-The-Counter Use (21 CFR 801 Subpart C) |
| <span style="font-size:120%;">☑</span> Prescription Use (Part 21 CFR 801 Subpart D) | | |
| <span style="font-size:120%;">☐</span> Over-The-Counter Use (21 CFR 801 Subpart C) | | |

#### CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

#### *DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.*

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

> Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff [e-mail]

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

{3}------------------------------------------------

Image /page/3/Picture/0 description: The image shows the logo for Fresenius Kabi. The logo consists of three blue, wavy lines on the left side. To the right of the lines, the words "FRESENIUS" and "KABI" are written in blue, with "KABI" on the second line. The logo is simple and modern, and the blue color gives it a sense of trustworthiness.

Fresenius Kabi Three Corporate Drive Lake Zurich, Illinois 60047 T 847-550-2300 T 888-391-6300 www.fresenius-kabi.us

K210089

# 510(k) SUMMARY

## Date Prepared

11th February 2021

## Owner/Operator

Owner/Operator Owner/Operator #: 9027285 Fresenius Kabi AG Bad Homburg, GERMANY 61346

#### Contact Person (include full address, phone and fax numbers)

| Contact Name: | Deepak Mehta |
|-------------------------|---------------------------------------------------------------------------------|
| Title: | Sr. Regulatory Specialist |
| Address: | Fresenius Kabi<br>Three Corporate Drive, 2nd Floor<br>Lake Zurich, IL 60047 USA |
| Telephone: | 847-550-2666 |
| Fax: | 847-550-2960 |
| E-mail: | [e-mail] |
| Official Correspondent: | Cheryl Roscher |
| Title: | Vice President, Regulatory and Clinical Affairs |
| Address: | Fresenius Kabi<br>Three Corporate Drive, 2nd Floor<br>Lake Zurich, IL 60047 USA |
| Telephone: | 847-550-7909 |
| Fax: | 847-550-2960 |
| E-mail: | [e-mail] |

### Device Trade Name

#### CATSmart

## Common Name/Usual Name:

Automated Blood Processing Autotransfusion System

#### Classification Name

Class II per 21 CFR 868.5830 Apparatus, Autotransfusion

## Product Code

CAC, Anesthesiology

{4}------------------------------------------------

Image /page/4/Picture/0 description: The image contains the logo for Fresenius Kabi. The logo consists of two parts: a graphic element on the left and the company name on the right. The graphic element is composed of three blue, curved lines arranged vertically, resembling stylized waves or streams. To the right of the graphic, the words "FRESENIUS" and "KABI" are stacked on top of each other, both in a bold, sans-serif typeface and in blue.

Fresenius Kabi Three Corporate Drive Lake Zurich, Illinois 60047 T 847-550-2300 T 888-391-6300 www.fresenius-kabi.us

| 510(k) Number | K192368 |
|---------------------|---------------------------------------------------|
| Device Name | CATSmart |
| Common Name | Automated Blood Processing Autotransfusion System |
| Classification | Class II per 21CFR868.5830 |
| Classification Name | Apparatus, Autotransfusion |
| Product Code | CAC |
| Review Panel | Cardiovascular |
| Manufacturer | Fresenius Kabi AG |

## Legally Marketed Device Under Which Substantial Equivalence is Being Claimed

## Device Description

The Fresenius Kabi CATSmart device is an intraoperative autotransfusion system for intra- and/or postoperative processing of blood lost through surgery or trauma. The CATSmart device operates on the principle of a continuous flow centrifuge, comparable to continuous systems for hemapheresis which, for decades, have been widely used in blood banks.

In a typical CATSmart procedure, the shed blood, which is anticoagulated and collected in a sterile reservoir, is processed in a continuous washing process to obtain washed packed red cells for reinfusion to the patient. During this process all plasmatic and nonerythrocytic cellular components of the collected blood, and thus activated coagulation factors, products of fibrinolysis and cell trauma as well as the anticoagulant are removed. The packed red cells are collected in a reinfusion bag from which they can be reinfused to the patient via a transfusion set when needed.

The system includes disposable sets and accessories previously cleared by FDA in respective 510(k)'s.

## Indications for Use

The CATSmart System by Fresenius Kabi is an autotransfusion device indicated for the processing of autologous shed blood collected intraoperatively and postoperatively to obtain washed packed red blood cells for reinfusion. Additionally, it can be used for perioperative separation of blood into Packed Red Cells (PRC), Plasma (PLS) and Platelet Rich Plasma (PRP).

## Technological Comparison as Compared to the Predicate Device

There is no change to CATsmart device design, materials, specifications, technological characteristics and function of the CATSmart disposable sets and accessories.

{5}------------------------------------------------

Image /page/5/Picture/0 description: The image contains the logo for Fresenius Kabi. The logo consists of three blue, wavy lines on the left side. To the right of the lines, the words "FRESENIUS" and "KABI" are stacked on top of each other, also in blue.

Fresenius Kabi Three Corporate Drive Lake Zurich, Illinois 60047 T 847-550-2300 T 888-391-6300 www.fresenius-kabi.us

### Modification to the Existing Device

There is no design change to the FDA-cleared disposable sets and accessories. Manufacturing process and sterilization methods in the new site remain the same as previously cleared.

## Performance Data

As part of the comprehensive sterility assurance program for the validation of this product, bioburden testing, verification of bacterial endotoxin and a performance qualification including biological indicators (BIs), temperature mapping, relative humidity, ethylene oxide concentration and residual testing was performed.

The sterilization validation results demonstrate that the sterilization activities performed do not impact the safety, effectiveness, quality, or fundamental technology of the CATSmart disposable sets and accessories.

### Clinical Data

No clinical data was required to support the changes described in this submission.

#### Conclusion

The fundamental scientific technology, intended use, safety and effectiveness of the CATSmart Continuous Autotransfusion System including disposable sets and accessories remain the same. The validation activities performed in support of the change described in this application provide evidence that the proposed device is substantially equivalent to the predicate device.